It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

Novo Nordisk President and CEO Lars Fruergaard Jorgensen, shown testifying on Capitol Hill in September, is warning about potential risks from compounded versions of the drug semaglutide.

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...

because there’s only one semaglutide, and that’s produced by Novo Nordisk, and we don’t sell that to others.” Compounded drugs are made by pharmacies or manufacturers other than the companies that ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that the ...